Management
analyse_media
analyse_media
Reading File
Finding Sources
Finding Sources
Searching PubMed
occluded LIMA LAD graft CABG management redo revascularization
Finding Sources
Finding Sources
Searching PubMed
coronary artery disease post CABG revascularization guidelines
Reading File
Reading File
Searching PubMed
chronic total occlusion LAD medical therapy options
Reading File
Finding Sources
I now have sufficient information to provide a comprehensive management response. Here is a structured answer based on the CT coronary angiography findings.
CT Coronary Angiography - Report Summary
Patient: Mohideen Batcha, Male, 71 years
Background: Post-CABG (2014), Post-PTCA, Post-PPI - Diabetes, Dyslipidemia, Hypertension
EF: 62%, Mild AR, concentric LVH, mildly sclerosed AV
Key Findings (CTCA - 640 Slice, 30/06/2026)
| Vessel / Graft | Status |
|---|---|
| LIMA to LAD | Occluded |
| Proximal & Mid LAD stents | Occluded |
| Distal LAD | Diffusely critically diseased, points of occlusion |
| Diagonal branches | Critically diseased, occluded |
| RSVG to OM2 | Patent - proximal mild 30% stenosis only |
| LCX | Non-dominant; mid segment focal band occlusion; distal significant stenosis |
| Last OM | Diffusely diseased with critical stenosis |
| RCA (dominant) | Proximal 30-40% stenosis, rest mild - no significant stenosis |
| PDA / PLV | No significant stenosis |
| Native LMCA | No significant stenosis |
| LV | Not dilated, no aneurysm, EF preserved |
| Pacemaker lead | In RV apex and RA - intact |
Management Approach
This is a complex post-CABG patient with multiple graft/stent failures in the LAD territory but a preserved EF (62%) and patent OM graft. The clinical picture determines urgency - the approach differs based on whether the patient is presenting with stable angina, ACS, or is asymptomatic.
1. Assess Clinical Presentation First
- Is the patient symptomatic (angina, dyspnoea, ACS)? Or was this CTCA surveillance?
- Check current medications and recent functional testing
- ECG and troponin if any acute symptoms
2. Intensive Guideline-Directed Medical Therapy (GDMT) - Mandatory
This is the foundation regardless of revascularization decisions:
Antiplatelet:
- Aspirin 75-100 mg daily (indefinitely post-CABG/stent)
- Consider dual antiplatelet (aspirin + clopidogrel/ticagrelor) if there is evidence of recent ACS or stent thrombosis
High-intensity statin:
- Atorvastatin 40-80 mg or Rosuvastatin 20-40 mg
- Target LDL < 55 mg/dL (very high cardiovascular risk category)
- Add ezetimibe or PCSK9 inhibitor if LDL not at goal
Beta-blocker:
- Continue or optimise (e.g., metoprolol succinate/bisoprolol)
- Already on metoprolol per pre-medication list
ACE inhibitor / ARB:
- Mandatory with LVH and diabetes - ramipril/perindopril
Anti-anginal therapy (if symptomatic):
- Long-acting nitrates (isosorbide mononitrate) - caution with PPI interaction
- Ranolazine - useful in refractory angina with preserved EF
- Ivabradine if sinus rhythm with HR > 70 and on max beta-blocker
- Nicorandil / trimetazidine (available in India) as adjuncts
Diabetes optimisation:
- SGLT2 inhibitor (empagliflozin/dapagliflozin) - cardiovascular outcome benefit
- GLP-1 agonist if obese
- Target HbA1c individualised (~7-7.5% in elderly)
Blood pressure control:
- Target < 130/80 mmHg in diabetic CAD patient
Anticoagulation:
- No indication for anticoagulation unless AF is detected (has pacemaker - check rhythm)
3. Revascularization Decision - Heart Team Discussion
This patient has:
- Occluded LIMA-LAD (failed arterial graft - 10 years post-CABG)
- Occluded proximal and mid LAD stents (likely in-stent restenosis/thrombosis)
- Diffusely diseased distal LAD - poor target
- Preserved EF (62%) - no large viability issue apparent
- Patent RSVG-OM2 - protecting lateral wall
Redo CABG (Re-operation):
- High risk in a 71-year-old with prior CABG and pacemaker
- LAD territory: native vessel is diffusely diseased distally - questionable target quality
- Would require new conduit (radial artery / alternate SVG)
- Consider only if large viable territory at risk and symptoms are refractory to medical therapy
- Operative mortality of redo CABG is significantly higher than primary CABG
PCI Options:
- RSVG: Not needed currently (already patent, no significant stenosis in graft)
- Native LAD / stented segments: CTO-PCI of proximal/mid LAD could be considered, but:
- Diffusely diseased distal vessel is a poor runoff
- High procedural complexity (prior stents + CTO)
- Benefit uncertain given diffuse distal disease
- LCX/OM disease: Distal LCX has significant stenosis - may be a target if symptomatic
- Decision depends on whether viable myocardium at risk can be demonstrated
Viability / Ischaemia Testing:
- If EF is preserved and patient is minimally symptomatic, medical therapy is reasonable
- If significant angina persists, perform:
- Stress MRI or nuclear perfusion scan (SPECT/PET) to quantify ischaemic territory
- Hibernating myocardium in LAD territory would favour revascularisation attempt
- If no significant viability, medical therapy alone is appropriate
4. Refractory Angina Options (if revascularization not feasible)
Per Goldman-Cecil Medicine and Harrison's:
- Enhanced External Counterpulsation (EECP): 35 sessions over 7 weeks - improves angina symptoms and quality of life in patients not candidates for revascularization
- Spinal cord stimulation - for refractory angina
- Transmyocardial laser revascularization - limited data, last resort
- Cardiac rehabilitation - highly recommended in all post-CABG patients
5. Monitoring & Follow-up
- Cardiology review within 2-4 weeks with functional assessment
- Pacemaker check (lead in RV apex + RA seen) - ensure appropriate programming
- Renal function monitoring (ACEi/ARB + contrast exposure)
- Lipid profile, HbA1c, renal panel in 3 months
- Echocardiogram in 6-12 months to reassess EF and wall motion
- Patient education: chest pain action plan, smoking cessation (if applicable), dietary counselling
Summary - Priority Actions
| Priority | Action |
|---|---|
| Immediate | Optimise GDMT (antiplatelet, high-intensity statin, beta-blocker, ACEi, SGLT2i) |
| Urgent | Cardiology/Heart Team review for revascularization decision |
| If symptomatic | Stress imaging (MRI/SPECT) to assess viability in LAD territory |
| Consider | CTO-PCI of LAD or LCX if significant ischaemia documented |
| Avoid | Redo CABG unless no other option and large viable territory at risk |
| Long-term | EECP if refractory angina, cardiac rehab, close monitoring |
Key point: This patient's LAD territory has failed grafts, failed stents, and diffusely diseased native vessels - re-revascularisation will be technically challenging. Preserved EF (62%) suggests absence of extensive infarction. Optimised medical therapy is the cornerstone; any revascularization should be guided by demonstrating significant ischaemia and viable myocardium in the affected territory, ideally discussed by a multidisciplinary Heart Team.
The 2021 ACC/AHA/SCAI Coronary Revascularization Guidelines (PMID 34895951) strongly endorse guideline-directed medical therapy as the foundation and require evidence of significant ischaemia before recommending revascularization in stable patients.
Disclaimer: This analysis is for educational/discussion purposes. All management decisions must be made by the treating cardiologist/cardiac surgeon after full clinical assessment.
This is a shared conversation. Sign in to Orris to start your own chat.